Novo Nordisk A/S (NVO)
Novo Nordisk A/S is a global healthcare company based in Denmark, specializing in the research, development, and manufacturing of pharmaceutical products. The company is a leader in diabetes care and is also involved in areas such as hemophilia care, growth hormone therapy, and hormone replacement therapy. Additionally, Novo Nordisk produces the successful weight loss drug, Wegovy.
Company Info
Highlights
$494.05B
$3.03
35.33
1.62
$199.27B
$169.07B
$98.21B
$93.70 - $147.59
$142.36
0.19%
1.26
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Novo Nordisk A/S, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Novo Nordisk A/S had a return of -2.11% year-to-date (YTD) and -0.13% in the last 12 months. Over the past 10 years, Novo Nordisk A/S had an annualized return of 18.69%, outperforming the S&P 500 benchmark which had an annualized return of 11.16%.
NVO
-2.11%
-15.18%
-24.36%
-0.13%
31.95%
18.69%
^GSPC (Benchmark)
23.62%
0.54%
11.19%
30.63%
13.61%
11.16%
Monthly Returns
The table below presents the monthly returns of NVO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 10.91% | 4.38% | 7.98% | -0.07% | 5.43% | 5.51% | -7.08% | 5.32% | -14.44% | -5.98% | -2.11% | ||
| 2023 | 2.54% | 1.59% | 13.77% | 5.00% | -3.97% | 0.85% | -0.45% | 15.77% | -2.01% | 6.19% | 5.46% | 1.58% | 54.83% |
| 2022 | -10.83% | 3.08% | 8.89% | 2.66% | -3.16% | 0.93% | 4.16% | -8.09% | -6.10% | 9.24% | 14.48% | 8.62% | 22.63% |
| 2021 | -0.36% | 2.37% | -4.02% | 9.69% | 6.69% | 6.17% | 10.54% | 8.54% | -3.96% | 14.71% | -3.00% | 4.84% | 63.51% |
| 2020 | 5.10% | -4.44% | 5.01% | 5.20% | 4.12% | -0.70% | -0.23% | 1.88% | 5.13% | -7.98% | 5.07% | 4.05% | 23.32% |
| 2019 | 2.06% | 4.10% | 8.48% | -6.31% | -3.69% | 8.14% | -6.11% | 9.72% | -0.79% | 6.81% | 1.68% | 3.08% | 28.67% |
| 2018 | 3.41% | -7.24% | -3.01% | -4.69% | 1.28% | -2.99% | 7.91% | -0.24% | -4.13% | -8.40% | 7.97% | -1.18% | -12.12% |
| 2017 | 0.86% | -2.32% | -1.01% | 12.84% | 9.54% | 1.23% | -1.14% | 13.47% | 1.11% | 3.41% | 3.98% | 3.67% | 54.26% |
| 2016 | -3.81% | -8.00% | 7.28% | 2.95% | 0.45% | -4.03% | 5.93% | -17.20% | -10.98% | -14.55% | -5.46% | 6.73% | -36.56% |
| 2015 | 5.29% | 7.16% | 13.56% | 5.39% | 0.37% | -3.05% | 7.67% | -6.26% | -1.86% | -1.95% | 3.37% | 5.66% | 39.39% |
| 2014 | 7.36% | 19.81% | -2.16% | -0.57% | -6.85% | 9.25% | -0.30% | -0.20% | 3.61% | -5.12% | 0.62% | -6.91% | 16.67% |
| 2013 | 12.95% | -5.07% | -5.97% | 9.37% | -8.79% | -3.81% | 9.00% | -1.17% | 1.37% | -1.51% | 7.24% | 3.37% | 15.35% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of NVO is 41, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Novo Nordisk A/S provided a 1.44% dividend yield over the last twelve months, with an annual payout of $1.44 per share. The company has been increasing its dividends for 6 consecutive years.
| Period | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $1.44 | $1.04 | $0.81 | $0.75 | $0.65 | $0.62 | $0.57 | $0.57 | $0.71 | $0.38 | $0.42 | $0.32 |
Dividend yield | 1.44% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% | 1.72% |
Monthly Dividends
The table displays the monthly dividend distributions for Novo Nordisk A/S. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | $0.00 | $0.00 | $0.93 | $0.00 | $0.00 | $0.00 | $0.00 | $0.51 | $0.00 | $0.00 | $0.00 | $1.44 | |
| 2023 | $0.00 | $0.00 | $0.59 | $0.00 | $0.00 | $0.00 | $0.00 | $0.44 | $0.00 | $0.00 | $0.00 | $0.00 | $1.04 |
| 2022 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.00 | $0.00 | $0.29 | $0.00 | $0.00 | $0.00 | $0.00 | $0.81 |
| 2021 | $0.00 | $0.00 | $0.47 | $0.00 | $0.00 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.00 | $0.00 | $0.75 |
| 2020 | $0.00 | $0.00 | $0.39 | $0.00 | $0.00 | $0.00 | $0.00 | $0.26 | $0.00 | $0.00 | $0.00 | $0.00 | $0.65 |
| 2019 | $0.00 | $0.00 | $0.39 | $0.00 | $0.00 | $0.00 | $0.00 | $0.22 | $0.00 | $0.00 | $0.00 | $0.00 | $0.62 |
| 2018 | $0.00 | $0.00 | $0.34 | $0.00 | $0.00 | $0.00 | $0.00 | $0.23 | $0.00 | $0.00 | $0.00 | $0.00 | $0.57 |
| 2017 | $0.00 | $0.00 | $0.33 | $0.00 | $0.00 | $0.00 | $0.00 | $0.24 | $0.00 | $0.00 | $0.00 | $0.00 | $0.57 |
| 2016 | $0.00 | $0.00 | $0.48 | $0.00 | $0.00 | $0.00 | $0.00 | $0.22 | $0.00 | $0.00 | $0.00 | $0.00 | $0.71 |
| 2015 | $0.00 | $0.00 | $0.38 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.38 |
| 2014 | $0.00 | $0.00 | $0.42 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.42 |
| 2013 | $0.32 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.32 |
Dividend Yield & Payout
Dividend Yield
Payout Ratio
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Novo Nordisk A/S. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Novo Nordisk A/S was 71.30%, occurring on Oct 19, 1987. Recovery took 835 trading sessions.
The current Novo Nordisk A/S drawdown is 31.57%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -71.3% | Sep 21, 1983 | 1031 | Oct 19, 1987 | 835 | Feb 6, 1991 | 1866 |
| -51.24% | Aug 7, 2001 | 247 | Aug 5, 2002 | 381 | Feb 9, 2004 | 628 |
| -46.15% | Aug 4, 2015 | 332 | Nov 23, 2016 | 289 | Jan 19, 2018 | 621 |
| -42.91% | May 5, 1998 | 222 | Mar 22, 1999 | 300 | May 26, 2000 | 522 |
| -41.2% | Apr 9, 2008 | 257 | Apr 15, 2009 | 210 | Feb 12, 2010 | 467 |
Volatility
Volatility Chart
The current Novo Nordisk A/S volatility is 6.98%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Novo Nordisk A/S compared to its peers in the Biotechnology industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for NVO in comparison to other companies of the Biotechnology industry. Currently, NVO has a PE value of 35.3. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for NVO in comparison to other companies of the Biotechnology industry. Currently, NVO has a PEG value of 1.6. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Novo Nordisk A/S.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |